ICER, CADTH, and NICE collaborate to increase transparency in health technology evaluations
The Institute for Clinical and Economic Review (ICER), the Canadian Agency for Drugs and Technologies in Health (CADTH), and the UK’s National Institute for Health and Care Excellence (NICE) have announced changes to the way confidential information about health technologies is handled. The aim is to streamline processes and increase transparency while balancing the need to protect confidential information. The three organizations have been working together to create a more consistent approach to handling clinical data. ICER has updated its academic-in-confidence data policy, reducing the period during which data is redacted from external and public documents from 18 months to 12 months. These changes will come into effect in May 2023.
Recent Posts
Advancing Collaborative TB Innovation to Tackle Drug Resistance
Collaborative TB Innovation is essential to ending the world’s deadliest infectious disease. Tuberculosis (TB) still claims millions of lives each year, with rising drug resistance, climate-driven migration, and conflict severely undermining global progress. While the burden falls heaviest on low...
Citation Analysis of Real-World Evidence in Medicare Drug Price Negotiations
Medicare Drug Price Negotiations are increasingly relying on real-world evidence, according to a new citation analysis of the first drugs selected under the Inflation Reduction Act. The study examined how the Centers for Medicare and Medicaid Services (CMS) uses real-world evidence (RWE) in its M...
Serplulimab Lung Cancer Treatment: Evaluation of Clinical and Economic Impact in Portugal
Serplulimab lung cancer treatment has received a positive funding recommendation from Portuguese authorities for first-line use in extensive-stage small cell lung cancer (ES-SCLC), despite not demonstrating added therapeutic value over the current standard.
No Added Therapeutic Value...